{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:51:57Z","timestamp":1785768717503,"version":"3.56.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302582"],"award-info":[{"award-number":["82302582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Health Commission Project","award":["20224Y0317"],"award-info":[{"award-number":["20224Y0317"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The early diagnosis of primary CNS lymphoma (PCNSL) is challenging due to its rapid progression and the lack of reliable noninvasive biomarkers. We aimed to identify robust fluid-based biomarkers for PCNSL, with a focus on primary vitreoretinal lymphoma (PVRL), which is a diagnostically difficult subtype given the scarcity and fragility of lymphoma cells in the vitreous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using retrospective cohorts (PCNSL\/PVRL = 199; controls = 179) and nested case-control cohorts within large hospital-based (n = 100 526) and population-based (n = 515 326) settings, we performed proteomic screening with the Olink Reveal 1034 and Explore 3072 platforms, followed by ELISA validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hepatitis A virus cellular receptor 1 (HAVCR1) emerged as the only consistent and significant biomarker distinguishing PVRL from both normal and uveitic controls, yielding AUCs of 0.916 in the aqueous humor and 0.997 in an independent validation cohort. In the population-based nested case-control analysis, HAVCR1 achieved an AUC of 0.948, thus supporting its robustness in real-world screening scenarios. In the cerebrospinal fluid, HAVCR1 demonstrated exceptional diagnostic accuracy for PCNSL (AUCs: 0.999 and 0.969 in 2 validation cohorts). In prospective follow-up cohorts, HAVCR1 levels significantly decreased after complete remission (P &amp;lt; 0.05), thereby suggesting utility for treatment monitoring. Single-nucleus RNA sequencing demonstrated HAVCR1 expression restricted to malignant B-cell clusters, which was consistent with immunohistochemistry results in tissues and lymphoma cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings establish HAVCR1 as a tumor-derived, fluid-accessible biomarker with high diagnostic performance for PCNSL and PVRL, thus supporting a minimally invasive strategy for early diagnosis and longitudinal monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvag036","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:53:42Z","timestamp":1773838422000},"page":"880-892","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-Derived HAVCR1 As a Reliable Fluid Biomarker for the Diagnosis of CNS Lymphoma"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-740X","authenticated-orcid":false,"given":"Shengjie","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shanghai Xuhui Central Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026080309514306800_hvag036-B1","author":"Swerdlow"},{"key":"2026080309514306800_hvag036-B2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2026080309514306800_hvag036-B3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2026080309514306800_hvag036-B4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026080309514306800_hvag036-B5","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"2026080309514306800_hvag036-B6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"key":"2026080309514306800_hvag036-B7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-020-03547-z","article-title":"Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study","volume":"148","author":"Velasco","year":"2020","journal-title":"J Neurooncol"},{"key":"2026080309514306800_hvag036-B8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17747","article-title":"Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom","volume":"195","author":"Kaji","year":"2021","journal-title":"Br J Haematol"},{"key":"2026080309514306800_hvag036-B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026080309514306800_hvag036-B10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026080309514306800_hvag036-B11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"key":"2026080309514306800_hvag036-B12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"2026080309514306800_hvag036-B13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","article-title":"Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"18","author":"Grimm","year":"2007","journal-title":"Ann Oncol"},{"key":"2026080309514306800_hvag036-B14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/09273948.2020.1787460","article-title":"Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center","volume":"29","author":"Giuffr\u00e8","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"2026080309514306800_hvag036-B15","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"2026080309514306800_hvag036-B16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/09273948.2013.848905","article-title":"Diagnostic procedures in vitreoretinal lymphoma","volume":"22","author":"Dalal","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"2026080309514306800_hvag036-B17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2004.05028.x","article-title":"Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment","volume":"126","author":"Hormigo","year":"2004","journal-title":"Br J Haematol"},{"key":"2026080309514306800_hvag036-B18","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S2352-3026(24)00104-2","article-title":"Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10","volume":"11","author":"Calimeri","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026080309514306800_hvag036-B19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ophtha.2020.01.042","article-title":"Logistic regression classification of primary vitreoretinal lymphoma versus uveitis by interleukin 6 and interleukin 10 levels","volume":"127","author":"Kuo","year":"2020","journal-title":"Ophthalmology"},{"key":"2026080309514306800_hvag036-B20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026080309514306800_hvag036-B21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/neuonc\/nor203","article-title":"Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)","volume":"14","author":"Sasayama","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026080309514306800_hvag036-B22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.survophthal.2023.12.001","article-title":"Diagnostic methods for primary vitreoretinal lymphoma: a systematic review","volume":"69","author":"Huang","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"2026080309514306800_hvag036-B23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ophtha.2016.01.037","article-title":"ISOLD: a new highly sensitive interleukin score for intraocular lymphoma diagnosis","volume":"123","author":"Costopoulos","year":"2016","journal-title":"Ophthalmology"},{"key":"2026080309514306800_hvag036-B24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10384-009-0662-y","article-title":"Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid","volume":"53","author":"Sugita","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"2026080309514306800_hvag036-B25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10384-012-0150-7","article-title":"Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma","volume":"56","author":"Kimura","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"2026080309514306800_hvag036-B26","volume-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017","edition":"Revised 4th Ed"},{"key":"2026080309514306800_hvag036-B27","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2026080309514306800_hvag036-B28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41375-025-02562-1","article-title":"Establishment and molecular characterisation of patient-derived organoids for primary central nervous system lymphoma","volume":"39","author":"Li","year":"2025","journal-title":"Leukemia"},{"key":"2026080309514306800_hvag036-B29","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1002\/cam4.930","article-title":"Expression of Tim-1 in primary CNS lymphoma","volume":"5","author":"Kishimoto","year":"2016","journal-title":"Cancer Med"},{"key":"2026080309514306800_hvag036-B30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10517-019-04533-w","article-title":"Kidney injury molecule-1 (KIM-1) in blood plasma of patients with clear-cell carcinoma","volume":"167","author":"Kushlinskii","year":"2019","journal-title":"Bull Exp Biol Med"},{"key":"2026080309514306800_hvag036-B31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","article-title":"The genome sequence archive family: toward explosive data growth and diverse data types","volume":"19","author":"Chen","year":"2021","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2026080309514306800_hvag036-B32","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1093\/nar\/gkab951","article-title":"Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022","volume":"50","author":"CNCB-NGDC Members and Partners","year":"2022","journal-title":"Nucleic Acids Res"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/8\/880\/68273772\/hvag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/8\/880\/68273772\/hvag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:51:54Z","timestamp":1785765114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/72\/8\/880\/8676546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvag036","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,21]]}}}